H.C. Stanton

1.3k total citations
43 papers, 1.1k citations indexed

About

H.C. Stanton is a scholar working on Physiology, Cardiology and Cardiovascular Medicine and Animal Science and Zoology. According to data from OpenAlex, H.C. Stanton has authored 43 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Physiology, 11 papers in Cardiology and Cardiovascular Medicine and 10 papers in Animal Science and Zoology. Recurrent topics in H.C. Stanton's work include Cardiac Ischemia and Reperfusion (7 papers), Cardiac electrophysiology and arrhythmias (6 papers) and Pharmacological Effects and Assays (6 papers). H.C. Stanton is often cited by papers focused on Cardiac Ischemia and Reperfusion (7 papers), Cardiac electrophysiology and arrhythmias (6 papers) and Pharmacological Effects and Assays (6 papers). H.C. Stanton collaborates with scholars based in United States, Netherlands and Germany. H.C. Stanton's co-authors include L.A. Riblet, Duncan P. Taylor, Michael S. Eison, Steven M. Seiler, Arlene S. Eison, Davis L. Temple, Harry J. Mersmann, Todd G. Kirchgessner, O.D. Gulati and K.W. Dungan and has published in prestigious journals such as Diabetes, Critical Care Medicine and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

H.C. Stanton

42 papers receiving 954 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H.C. Stanton United States 16 367 353 191 149 132 43 1.1k
W.J. Lang Australia 19 390 1.1× 328 0.9× 219 1.1× 120 0.8× 23 0.2× 42 1.0k
J R Boissier France 18 584 1.6× 296 0.8× 126 0.7× 72 0.5× 45 0.3× 58 1.1k
Walter F. Riker United States 23 426 1.2× 544 1.5× 214 1.1× 110 0.7× 36 0.3× 54 1.2k
A. Rubenson Sweden 18 761 2.1× 424 1.2× 338 1.8× 63 0.4× 42 0.3× 42 1.6k
E.B. Sigg United States 16 466 1.3× 336 1.0× 201 1.1× 121 0.8× 71 0.5× 36 1.3k
M.E. Goldberg United States 18 426 1.2× 405 1.1× 78 0.4× 201 1.3× 36 0.3× 59 1.1k
Margarethe Holzbauer Slovakia 21 396 1.1× 292 0.8× 229 1.2× 35 0.2× 87 0.7× 49 1.4k
Yehuda Gutman Israel 22 436 1.2× 699 2.0× 268 1.4× 218 1.5× 41 0.3× 91 1.5k
F. J. E. Stefano Argentina 20 636 1.7× 635 1.8× 260 1.4× 112 0.8× 48 0.4× 52 1.2k
Marilyn E. Hess United States 15 178 0.5× 327 0.9× 187 1.0× 229 1.5× 44 0.3× 55 921

Countries citing papers authored by H.C. Stanton

Since Specialization
Citations

This map shows the geographic impact of H.C. Stanton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.C. Stanton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.C. Stanton more than expected).

Fields of papers citing papers by H.C. Stanton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.C. Stanton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.C. Stanton. The network helps show where H.C. Stanton may publish in the future.

Co-authorship network of co-authors of H.C. Stanton

This figure shows the co-authorship network connecting the top 25 collaborators of H.C. Stanton. A scholar is included among the top collaborators of H.C. Stanton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.C. Stanton. H.C. Stanton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fleming, John, et al.. (1989). Pharmacology of a potent, new antithrombotic agent, 1,3-dihydro-7,8-dimethyl-2-imidazo[4,5-]quinolin-2-one (BMY-20844). Thrombosis Research. 56(3). 333–346. 11 indexed citations
2.
Stanton, H.C., Lois B. Rosenberger, Ruth Hanson, Jean S. Fleming, & Graham S. Poindexter. (1988). Pharmacology of BMY 20064, a Potent Ca2+ Entry Blocker and Selective α1-Adrenoceptor Antagonist. Journal of Cardiovascular Pharmacology. 11(4). 387–395. 10 indexed citations
3.
Fleming, John, et al.. (1988). The anesthetized ferret, an in vivo model for evaluating inotropic activity: Effects of milrinone and anagrelide. Journal of Pharmacological Methods. 20(4). 299–306. 10 indexed citations
4.
Seiler, Steven M., et al.. (1987). Inhibitors of inositol trisphosphate-induced Ca2+ release from isolated platelet membrane vesicles. Biochemical Pharmacology. 36(20). 3331–3337. 39 indexed citations
5.
Seiler, Steven M., et al.. (1987). Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes.. Journal of Pharmacology and Experimental Therapeutics. 243(2). 767–774. 37 indexed citations
6.
Grove, Robert I., et al.. (1986). Anagrelide, a potent inhibitor of platelet aggregation, inhibits inositol phosphate generation and elevates cAMP. Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States). 1 indexed citations
7.
Stanton, H.C.. (1986). Principles and Techniques of Human Research and Therapeutics. Critical Care Medicine. 14(8). 756–756. 4 indexed citations
8.
Stanton, H.C. & K.W. Dungan. (1986). In vitro effects of beta adrenoceptor agonists and antagonists on the rat ovarian suspensory ligament.. Journal of Pharmacology and Experimental Therapeutics. 239(2). 591–596. 7 indexed citations
9.
Stanton, H.C. & Harry J. Mersmann. (1986). Swine in Cardiovascular Research. 29 indexed citations
10.
Rosenberger, Lois B., et al.. (1984). Evaluation of cardiac anoxia and ischemia models in the rat using calcium antagonists. Life Sciences. 34(14). 1379–1387. 8 indexed citations
11.
Stanton, H.C., et al.. (1978). Development of adrenal medullary function in swine.. American Journal of Physiology-Endocrinology and Metabolism. 234(2). E137–E137. 6 indexed citations
12.
Stanton, H.C., et al.. (1974). Epinephrine-Induced Hyperglycemia and Glycogenolysis in Fed and Fasted Neonatal Swine. Neonatology. 25(5-6). 307–319. 4 indexed citations
13.
Stanton, H.C., et al.. (1973). Metabolic Responses Induced in Neonatal Swine by Norepinephrine, Epinephrine, and Isoproterenol. Experimental Biology and Medicine. 143(2). 492–494. 11 indexed citations
14.
Brenner, George M. & H.C. Stanton. (1970). Adrenergic mechanism responsible for submandibular salivary glandular hypertrophy in the rat.. PubMed. 173(1). 166–75. 24 indexed citations
15.
Stanton, H.C., et al.. (1970). ADRENERGIC MECHANISMS RESPONSIBLE FOR SUBMANDIBULAR SALIVARY GLANDULAR HYPERTROPHY IN THE RAT. Journal of Pharmacology and Experimental Therapeutics. 173(1). 166–175. 6 indexed citations
16.
Stanton, H.C., et al.. (1969). Studies on isoproterenol-induced cardiomegaly in rats. American Heart Journal. 77(1). 72–80. 160 indexed citations
17.
Stanton, H.C.. (1966). Estimation of grossly detectable isoproterenol-induced myocardiopathies in rats using the ridit transformation. Toxicology and Applied Pharmacology. 9(2). 218–224. 4 indexed citations
18.
Dungan, K.W., H.C. Stanton, & P.M. Lish. (1965). Amidephrine-I: Pharmacologic characterization of a sympathomimetic alkylsulfonamidophenethanolamine. International Journal of Neuropharmacology. 4(4). 219–234. 18 indexed citations
19.
Stanton, H.C., et al.. (1960). THE EFFECT OF GAMMA-AMINO-N-BUTYRIC ACID AND SOME RELATED COMPOUNDS ON THE CARDIOVASCULAR SYSTEM OF ANESTHETIZED DOGS. Journal of Pharmacology and Experimental Therapeutics. 128(3). 233–242. 32 indexed citations
20.
Stanton, H.C. & H.H. Keasling. (1956). Comparison of Noludar (Methylprylon) and Pentobarbital on Respiratory Minute Volume in Rabbits.. Experimental Biology and Medicine. 93(3). 555–557. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W.J. Lang Breakdown of academic impact, for papers by J R Boissier Breakdown of academic impact, for papers by Walter F. Riker Breakdown of academic impact, for papers by A. Rubenson Breakdown of academic impact, for papers by E.B. Sigg Breakdown of academic impact, for papers by M.E. Goldberg Breakdown of academic impact, for papers by Margarethe Holzbauer Breakdown of academic impact, for papers by Yehuda Gutman Breakdown of academic impact, for papers by F. J. E. Stefano Breakdown of academic impact, for papers by Marilyn E. Hess
Rankless by CCL
2026